135 related articles for article (PubMed ID: 8610984)
1. Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis.
Trentham DE
Ann N Y Acad Sci; 1996 Feb; 778():306-14. PubMed ID: 8610984
[No Abstract] [Full Text] [Related]
2. Oral tolerance in the control of experimental models of autoimmune disease.
Staines NA; Harper N
Z Rheumatol; 1995; 54(3):145-54. PubMed ID: 7660685
[TBL] [Abstract][Full Text] [Related]
3. Immunological basis of oral tolerance.
Mitchison A; Sieper J
Z Rheumatol; 1995; 54(3):141-4. PubMed ID: 7660684
[TBL] [Abstract][Full Text] [Related]
4. Arthritis: animal models of oral tolerance.
Staines NA; Harper N; Ward FJ; Thompson HS; Bansal S
Ann N Y Acad Sci; 1996 Feb; 778():297-305. PubMed ID: 8610983
[No Abstract] [Full Text] [Related]
5. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis.
Corrigall VM; Bodman-Smith MD; Fife MS; Canas B; Myers LK; Wooley P; Soh C; Staines NA; Pappin DJ; Berlo SE; van Eden W; van Der Zee R; Lanchbury JS; Panayi GS
J Immunol; 2001 Feb; 166(3):1492-8. PubMed ID: 11160188
[TBL] [Abstract][Full Text] [Related]
6. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.
Nagler-Anderson C; Bober LA; Robinson ME; Siskind GW; Thorbecke GJ
Proc Natl Acad Sci U S A; 1986 Oct; 83(19):7443-6. PubMed ID: 3463976
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.
Juan L; Xiao Z; Song Y; Zhijian Z; Jing J; Kun Y; Yuna H; Dongfa D; Lili D; Liuxin T; Fei L; Nan L; Fang Y; Yuying S; Yongzhi X
Hum Vaccin Immunother; 2015; 11(12):2777-83. PubMed ID: 26697972
[TBL] [Abstract][Full Text] [Related]
8. The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats.
Yoshino S
Exp Mol Pathol; 1995 Apr; 62(2):123-30. PubMed ID: 8549696
[TBL] [Abstract][Full Text] [Related]
9. [Type II collagen: from experimental arthritis to treatment of rheumatoid polyarthritis].
Boissier MC; Fournier C
Rev Rhum Ed Fr; 1994 Mar; 61(3):150-2. PubMed ID: 7920510
[No Abstract] [Full Text] [Related]
10. [Therapy with oral type II collagen as a new possibility of selective immunosuppression in therapy of rheumatoid arthritis].
Sieper J; Mitchison AN
Z Rheumatol; 1994; 53(2):53-8. PubMed ID: 8023585
[TBL] [Abstract][Full Text] [Related]
11. Presence and role of anti-citrullinated protein antibodies in experimental arthritis models.
Cantaert T; Teitsma C; Tak PP; Baeten D
Arthritis Rheum; 2013 Apr; 65(4):939-48. PubMed ID: 23280233
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with endosomal unknown epitopes produces therapeutic response in rheumatoid arthritis patients and modulates adjuvant arthritis of rats.
Caruso I; Santandrea S; Gismondo M; Lombardi A; Montrone F; Caruso EM; Sarzi Puttini P
J Transl Med; 2016 Jun; 14(1):162. PubMed ID: 27268027
[TBL] [Abstract][Full Text] [Related]
13. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models?
Stoop JN; Robinson JH; Hilkens CM
Ann Rheum Dis; 2011 Sep; 70(9):1526-33. PubMed ID: 21804099
[TBL] [Abstract][Full Text] [Related]
14. Oral tolerization as a treatment of rheumatoid arthritis.
Trentham DE
Rheum Dis Clin North Am; 1998 Aug; 24(3):525-36. PubMed ID: 9710885
[TBL] [Abstract][Full Text] [Related]
15. Antigen-specific therapy of rheumatoid arthritis.
Ichim TE; Zheng X; Suzuki M; Kubo N; Zhang X; Min LR; Beduhn ME; Riordan NH; Inman RD; Min WP
Expert Opin Biol Ther; 2008 Feb; 8(2):191-9. PubMed ID: 18194075
[TBL] [Abstract][Full Text] [Related]
16. Oral tolerance and the treatment of rheumatoid arthritis.
Weiner HL; Komagata Y
Springer Semin Immunopathol; 1998; 20(1-2):289-308. PubMed ID: 9836383
[No Abstract] [Full Text] [Related]
17. Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the fibronectin type III repeats of tenascin-C: Targeting fibronectin type III repeats of tenascin-C in rheumatoid arthritis.
Mehta BB; Tiwari A; Sharma S; Shukla A; Sharma M; Vasishta RK; Sen RK; Sharma A; Luthra-Guptasarma M
Int Immunopharmacol; 2018 May; 58():15-23. PubMed ID: 29529488
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in collagen-induced arthritis: past, present, and future.
Wooley PH
Am J Med Sci; 2004 Apr; 327(4):217-26. PubMed ID: 15084918
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral administration of type II collagen on rheumatoid arthritis.
Trentham DE; Dynesius-Trentham RA; Orav EJ; Combitchi D; Lorenzo C; Sewell KL; Hafler DA; Weiner HL
Science; 1993 Sep; 261(5129):1727-30. PubMed ID: 8378772
[TBL] [Abstract][Full Text] [Related]
20. Oral desensitization in the treatment of human immune diseases.
Vischer TL
Z Rheumatol; 1995; 54(3):155-7. PubMed ID: 7544938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
